Skip to main content
SpringerLink
Log in
Birkhäuser

TNF-alpha Inhibitors

  • Book
  • © 2006

Overview

Editors:
  1. Jeffrey M. Weinberg

    1. Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, New York, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Robin Buchholz

    1. Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, New York, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Comprehensive reviews of efficacy, applications, and safety of all TNF-alpha inhibitors
  • First volume that summarizes this material for all available TNF-alpha inhibitors
  • Preclinical and clinical data is presented
  • Includes supplementary material: sn.pub/extras

Part of the book series: Milestones in Drug Therapy (MDT)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (10 chapters)

  1. Front Matter

    Pages I-IX
    Download chapter PDF

  2. Introduction to TNF/pathophysiology of TNF

    • Patricia Malerich, Dirk M. Elston
    Pages 1-8

  3. History of development of TNF inhibitors

    • Seth R. Stevens, Ting H. Chang
    Pages 9-22

  4. Pharmacology of TNF inhibitors

    • Rahul Shukla, Ronald B. Vender
    Pages 23-44

  5. Etanercept in rheumatology

    • Jeffrey D. Greenberg, Mitsumasa Kishimoto
    Pages 45-54

  6. Etanercept in dermatology and off-label use

    • Noah Gratch, Andrew F. Alexis
    Pages 55-63

  7. Infliximab in rheumatology

    • Mihaela B. Taylor, Dahlia T. Lainer
    Pages 65-81

  8. Infliximab in dermatology, gastroenterology, and off-label use

    • Noah Scheinfeld
    Pages 83-99

  9. Adalimumab in rheumatology

    • Harry D. Fischer
    Pages 101-105

  10. Adalimumab in dermatology

    • Jennifer Clay Cather, Melodie Young
    Pages 107-114

  11. A review of the safety of the tumor necrosis inhibitors infliximab, etanercept, and adalimumab

    • Jeffrey M. Weinberg
    Pages 115-127

  12. Back Matter

    Pages 129-133
    Download chapter PDF
Back to top

Keywords

About this book

Over the last decade, the advent of biologic agents has greatly revolutionized therapeutic medicine in the management of chronic inflammatory diseases, such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Elucidation of the complex web of cytokine network and the roles of these cytokines in the pat- genesis of inflammatory disorders provided one of the key catalysts for the advancement of targeted biologic therapy in autoimmune and inflammatory diseases. TNF-? is known to play a crucial role in the pathogenesis of many chronic inflammatory diseases. Elevated levels of TNF-? have been demonstrated in Crohn’s disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, sugge- ing a role for TNF-? in their pathogenesis. Although TNF-? plays a critical role in the activation of innate and acquired immune responses, the persistence of the immune response and inappropriate production of TNF-? can produce pathological changes resulting from chronic inflammation and tissue damage. The purpose of this volume is to provide a comprehensive overview of the development, pharmacology, efficacy, and safety of the currently available TNF-? inhibitors – etanercept, infliximab, and adalimumab. The initial three chapters of the volume provide a background on the field on TNF-? and its inhibition. Chapter 1 provides an introduction to TNF and reviews the pathophysiology of this cytokine. Chapter 2 then presents the h- tory of the development of TNF inhibitors. The pharmacology of these agents is reviewed in Chapter 3.

Editors and Affiliations

  • Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, New York, USA

    Jeffrey M. Weinberg, Robin Buchholz

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation